Personalized Gene Therapy Treatment Market Report 2026

The personalized gene therapy treatment market size has grown exponentially in recent years. It will grow from $8.38 billion in 2025 to $10.11 billion in 2026 at a compound annual growth rate (CAGR) of 20.7%. The growth in the historic period can be attributed to increasing prevalence of genetic disorders, advancements in genomic sequencing technologies, early clinical success of targeted gene therapies, expansion of specialized gene therapy research centers, increasing investment in precision medicine.

The personalized gene therapy treatment market size is expected to see exponential growth in the next few years. It will grow to $21.23 billion in 2030 at a compound annual growth rate (CAGR) of 20.4%. The growth in the forecast period can be attributed to increasing regulatory approvals for personalized gene therapies, rising demand for customized oncology treatments, expansion of gene therapy manufacturing capabilities, growing integration of AI in therapy design, increasing adoption of pharmacogenomics-guided treatments. Major trends in the forecast period include increasing adoption of gene editing-based therapies, rising use of personalized treatment protocols, growing integration of companion diagnostics, expansion of viral and non-viral vector platforms, enhanced focus on precision oncology applications.

The rising prevalence of genetic disorders is expected to drive the growth of the personalized gene therapy treatment market in the coming years. Genetic disorders are conditions caused by abnormalities in DNA that interfere with normal body functions. The prevalence of genetic disorders is increasing due to advancing parental age, as older reproductive cells carry a higher risk of mutations that can be inherited by offspring. Personalized gene therapy targets genetic disorders by accurately correcting the defective genes responsible for the condition and customizing treatment according to an individual’s genetic profile, improving effectiveness and minimizing side effects. For example, in October 2024, according to the Cystic Fibrosis Trust, a UK-based charity supporting individuals with cystic fibrosis, approximately 11,148 cystic fibrosis patients were registered in 2022, and this number rose to 11,318 in 2023, representing a 1.5% year-over-year increase in patient registrations. Therefore, the rising prevalence of genetic disorders is fueling the growth of the personalized gene therapy treatment market.

Major companies operating in the personalized gene therapy treatment market are concentrating on forming strategic partnerships to enhance technological capabilities and deliver innovative therapies to patients more efficiently. Strategic partnerships are collaborative alliances between organizations that utilize each other’s strengths and resources for mutual growth and competitive advantage while sharing risks and benefits. For example, in May 2025, Aldevron, a US-based company specializing in the production of DNA, RNA, and proteins, partnered with Integrated DNA Technologies, a US-based provider of genomics solutions, to produce the world’s first mRNA-based personalized CRISPR therapy for an infant with a rare and life-threatening genetic disorder, urea cycle disorder (UCD). This N of 1 therapy was developed and administered in just six months by designing a custom guide RNA, an mRNA-encoded base editor, off-target safety services, and a clinically validated lipid nanoparticle delivery system. The development of this therapy represents a significant milestone in personalized in vivo base-editing treatments.

In July 2025, Eli Lilly and Company, a US-based pharmaceutical firm, acquired Verve Therapeutics, Inc. for $1.3 billion. Through this acquisition, Eli Lilly aims to broaden its portfolio into cardiovascular gene-editing therapies and enhance its position in the personalized gene therapy sector. Verve Therapeutics is a US-based clinical-stage company developing one-time base-editing gene therapies specifically targeting cardiovascular disease.

Major companies operating in the personalized gene therapy treatment market are Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., BGI Genomics Co. Ltd., Invitae Corporation, Guardant Health Inc., GeneDx LLC, Ancestry Inc., Oxford Nanopore Technologies plc, Genomic Health Inc., 23andMe Holding Co., Color Health Inc., Helix OpCo LLC, Personalis Inc., Dante Genomics, Gene By Gene Ltd., Veritas Genetics Inc., Futura Genetics, Nebula Genomics Inc., Pathway Genomics Corporation.

North America was the largest region in the personalized gene therapy treatment market in 2025. The regions covered in the personalized gene therapy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the personalized gene therapy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the personalized gene therapy treatment market by increasing costs of imported viral vectors, laboratory reagents, bioprocessing equipment, and advanced genetic sequencing tools required for therapy development and delivery. North America and Europe are most affected due to reliance on cross-border sourcing of specialized biologics and manufacturing inputs, while Asia-Pacific faces higher costs for advanced research infrastructure. These tariffs are raising development and treatment costs and extending commercialization timelines. However, they are also encouraging localized manufacturing, regional supply chain development, and increased domestic investment in gene therapy production capabilities.

The personalized gene therapy treatment market research report is one of a series of new reports that provides personalized gene therapy treatment market statistics, including personalized gene therapy treatment industry global market size, regional shares, competitors with a personalized gene therapy treatment market share, detailed personalized gene therapy treatment market segments, market trends and opportunities, and any further data you may need to thrive in the personalized gene therapy treatment industry. This personalized gene therapy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Personalized gene therapy treatment is a specialized medical approach that provides therapies specifically designed according to an individual’s distinct genetic makeup. It alters, corrects, or substitutes defective genes to directly target the root causes of genetic disorders. Personalized gene therapy treatment improves treatment accuracy, reduces side effects, and increases therapeutic efficacy.

The primary categories of personalized gene therapy treatments include targeted therapies and pharmacogenomics. Targeted therapies are developed to specifically modify or regulate certain genes linked to a disease, aiming to provide optimal therapeutic benefits while minimizing side effects. The vectors used can be viral or non-viral, and these therapies are delivered through various channels, including hospitals, clinics, home administration, and others, for applications across multiple medical specialties such as oncology, neurology, hematology, infectious diseases, ophthalmology, and more.

The personalized gene therapy treatment market consists of revenues earned by entities by providing services such as genetic testing and diagnostics, personalized therapy design, gene editing treatments, viral and non-viral vector delivery, patient-specific cell therapies, and post-treatment monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The personalized gene therapy treatment market also includes sales of viral vectors, gene editing platforms, cell culture systems, bioprocessing tools, and monitoring software. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.